Initial excitement associated with the completion of genome-scale CRISPR screens can quickly turn to dismay as the realisation of the sheer quantity of data generated becomes apparent. Extracting the most relevant biological data from such studies can seem daunting, but with the correct strategy, can be incredibly rewarding.
Drug discovery is a challenging process that is often hindered by inefficient target identification. Functional genomics has the potential to advance target identification strategies that are crucial to overcoming current limitations in oncology drug development processes. Wellcome Sanger Institute researchers have performed genome-scale CRISPR-Cas9 screening in 204 human cancer cell lines from 12 cancer-types and developed a data-driven framework to prioritise cancer therapeutic candidates. This webinar will describe the logic behind this framework including criteria used and also describe alternative metrics that could be included. Using published datasets, they assessed the current tractability of the target and included this in the candidate selection process.
Following the identification of the top candidate targets, key experimental verification and validation steps are required. In this webinar, our featured speaker will describe strategies to use published data to verify true positive hits, as well as experimental approaches. Selection of appropriate cellular models to carry out verification and validation experiments is an important factor to consider. The speaker will highlight cell models that are available and discuss the advantages and disadvantages of each system. Key factors to consider include verification of the target using independent reagents or technologies. Understanding the mechanism of action or functionality of the target in a model system is integral to assessing the suitability of a target to enter a drug development program. Revealing the cellular processes altered by perturbation of the target will indicate if cell death is induced, or if a reduction in cellular fitness reduces or halts cell growth.
Fiona Behan, Post-Doctoral Fellow, Wellcome Sanger Institute
Fiona Behan is a post-doctoral research fellow at the Wellcome Trust Sanger Institute. Following the completion of her PhD implementing siRNA screens to identify novel drug targets in oesophageal adenocarcinoma, Fiona spent 1 year at the Department of Veterinary Medicine, University of Cambridge. This project involved investigating the use of miRNA profiling to discriminate subsets of soft tissue sarcomas. Her current postdoctoral position with Mathew Garnett at the Sanger Institute utilises whole genome CRISPR drop-out screens in a panel of cancer cell lines to identify novel oncology drug targets.Message Presenter
Who Should Attend?
Academic & pharmaceutical researchers in basic research & drug discovery, including those who are interested in:
- Target validation with in vitro models
- Best practice examples or case studies
What You Will Learn
- Prioritisation of targets from genome-scale CRISPR screens from a drug development perspective
- Verification of candidate targets experimentally and using published data
- Experimental validation of mechanism of action of the candidate target
Horizon Discovery Group
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.
Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c. 1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.